Charles Slonim, MD
Chief Medical Officer
Dr. Charles B. Slonim most recently served as an Adjunct Professor of Ophthalmology and Affiliate Professor of Surgery, Division of Plastic Surgery, at the University of South Florida College of Medicine in Tampa and Associate Clinical Professor of Ophthalmology at the University of Florida College of Medicine in Gainesville, Florida. Dr. Slonim teaches physicians about oculoplastic diseases, diagnoses, and surgeries, as well as contact lens technology. He has lectured extensively to ophthalmologists, optometrists and other physicians throughout the United States, and in more than 55 international cities and 34 countries around the world. He served as a Consultant at the Olympic Vision Center in the Olympic Village during the 1992 Summer Olympics in Barcelona. He has been a world-renowned Consultant for a number of major contact lens and ophthalmic pharmaceutical companies. He served as a Member for the Scientific Advisory Board of Sirion Therapeutics, Inc. and Sirion Holdings Inc. He is the team Ophthalmologist for many Tampa Bay area professional and intercollegiate sports teams, including the Tampa Bay Lightning of the National Hockey League and the University of South Florida intercollegiate sports programs. He has published one book, Eye Was There: A Patient Guide to Coping with the Loss of an Eye; more than 36 scientific journal articles; 20 ophthalmic book chapters; and 11 clinical symposia. Dr. Slonim is a graduate of Johns Hopkins University and New York Medical College and completed an Internship in Ophthalmology from Mt. Sinai Medical Center in Cleveland and a Residency in Ophthalmology from Mt. Sinai Medical Center in Cleveland.
Drey Coleman has been responsible for the management of Oculos Clinical Research since May 2012, prior to which she provided operational guidance and support to the Oculos clinical project teams. She has more than 30 years of diverse experience in the areas of regulatory compliance, corporate governance, intellectual property rights, strategic planning, risk assessment and mitigation, due diligence, client/vendor management and global business development. She has extensive knowledge of the laws, regulations, and standards affecting the pharmaceutical industry. Drey also has significant experience in process design and execution. Drey has a Bachelor’s degree in Allied Legal Services from the University of Central Florida.
Director of Clinical Operations
Roselyn Judd has over 30 years of experience in ophthalmology and 25 years of experience in clinical research. She has been responsible for managing clinical trials for CROs, pharmaceutical companies and academic institutions. Prior to joining Oculos, Roz was a Global Clinical Site Developer for Alcon, Clinical Trials Manager at Vanderbilt University and the Director of Clinical Operations at Sirion Therapeutics. In her current position, Roz is responsible for the overall study and resource management for Oculos. Roz has her Bachelor of Science degree in Human Resource Development from Oakland University in Rochester, Michigan.
Director, Centralized Monitoring
Ms. Cardosa has 13 years of clinical research experience and joined Oculos in January 2013. She has worked on pediatric and adult studies with indications of Dry Eye, Glaucoma, Post-Op Inflammation, Uveitis, ARMD, Amblyopia, Nasolacrimal Duct Obstruction, Esotropia, Leukemia and Lymphoma. Esmeralda has experience with case report form creation, remote electronic data monitoring, on-site monitoring, data verification and coding, site selection, maintenance regulatory files, study start up, investigator meeting preparations and managing central monitoring. She has earned her CCRP certification through SOCRA and is currently in the process of obtaining her Bachelor of Science Degree from the University of Central Florida.
Kathleen Krenzer, OD, PhD, DABT
Research Fellow - Toxicology
Dr. Kathleen Krenzer is a board-certified toxicologist (DABT) serving as a Research Fellow in toxicology, with a focus on ophthalmic product development. Prior to joining iuvo BioScience, Kathleen was a Senior Principal Scientist at Bausch + Lomb in the nonclinical safety group. Kathleen’s expertise in nonclinical product development includes stems from her previous experiences as a Study Director at a contract research laboratory, overseeing both pharmaceutical and medical device testing while a principal/senior principal scientist at Bausch + Lomb where Kathleen covered both pharmaceutical and medical device developed programs, including 510(k), PMA, IND, and NDA submissions and geoexpansion activities, as well as nonclinical support for marketed products. As a clinician scientist, Kathleen brings a wealth of expertise in the area of ophthalmic product development, always maintaining focus on the ultimate beneficiary, the patient. Her background in ophthalmic development includes early discovery with testing in efficacy models through clinical evaluations, having served as part of clinical investigative teams for numerous ophthalmic products.
Business Development Executive
Ronil currently serves as the Business Development Executive for Oculos Development Services. Prior to that he served as the Director of Business Development and Project Management for Point Guard Partners and its subsidiaries – Oculos Clinical Research and OSD Innovations. He also serves as project lead for several projects leading to NDA submission. Ronil’s duties in his current role involve responding to RFPs, clinical trial budgeting, submitting proposals, soliciting bids from potential vendors, licensing technologies, clinical protocol development, and managing client relations. Prior to joining Point Guard Partners, Ronil worked in research and development labs in the area of drug discovery & drug delivery. His research has been published in peer-reviewed journals. He has vast knowledge and hands-on expertise in molecular biology, biochemistry and animal models for drug discovery and delivery. He has a thorough understanding of signal transduction pathways and has managed several projects involving development of small molecule inhibitors for Rho‑kinase, Proteasome, JAK, Akt, Stat3 and Aurora kinase. Ronil has a Master of Technology and a Master of Science degree in Biotechnology.
Mary Richardson, PhD, DABT
Chief Scientific Officer
As Chief Scientific Officer at iuvo BioScience and Oculos, Mary heads up the Research and Development team. Most recently Mary served as Executive Director of Preclinical Development at Bausch & Lomb, continuing in that role when Valeant Pharmaceuticals purchased the company. Previously, she was Director of Nonclinical Safety. Her extensive background includes in-depth research and development experience covering the full range of the preclinical product life cycle including discovery, product development and post-market support in areas including life cycle management, geo-expansion and manufacturing. Her knowledge of global regulations and standards for registration of pharmaceutical and medical device products is exhaustive. Her technical leadership and expertise in drug development of small molecules, peptides, and medical devices has resulted in regulatory approval and success of numerous NDAs, INDs, IMPDs, and 510(k) submissions. She’s an in-demand speaker with many published articles in scientific journals. Mary earned her PhD from the University of Rochester School of Medicine and Dentistry and is a highly experienced board-certified toxicologist (Diplomate of American Board of Toxicology – DABT) with broad-based technical skills in pharmaceuticals, OTC, medical devices, drug metabolism, toxicology, pharmacokinetics and pharmacology.
President and CEO
Prior to co-founding iuvo BioScience and taking on the roles of President and CEO, Ben was Vice President of Quality for the Pharmaceutical, Solutions and External Manufacturing organizations of Valeant Pharmaceuticals. Prior to the acquisition of Bausch + Lomb by Valeant, Ben served as Global VP of Quality for the Pharmaceutical Business Unit, and was a member of the B+L Global Leadership Team. Earlier in his career, he held the position of Director, Quality and Technical Services for Norwich Pharmaceuticals (a contract manufacturing and development organization), responsible for driving new business development and revenue. Ben also led Norwich’s technical services organization (project managers, engineers, formulators, method developers, etc.) in delivering customer projects, in addition to heading up the site quality organization. Ben began his career with Procter & Gamble Pharmaceuticals as a Process Engineer, moving up to roles of increasing responsibility in Product Development, OTC Engineering (Cayey, PR) and Global Clinical Supplies. Ben holds a BS from Carnegie Mellon University with a double major in Chemical Engineering and Biomedical Engineering, and a dual MS/MAT in Chemistry and Education from Binghamton University.